San Diego, CA, March 02, 2011 --(PR.com
)-- Dr. Greg Maguire and Peter Friedman, founders of BioRegenerative Sciences, Inc., a privately owned stem cell therapeutics corporation headquartered in San Diego, CA, USA, announced today the release of I-Ease, a topically applied eye drop for relieving the pain and irritation associated with dry eye. BioRegenerative Sciences' clinical studies of I-Ease demonstrated that the pain and irritation associated with dry eye was reduced or eliminated in a matter of days following the topical application of I-Ease. According to Dr. Greg Maguire, CEO and Chief Scientific Officer of BRS, "BRS' I-Ease restores the biochemical properties of the tear film and corneal surface to a healthy state so that the eye tissue is no longer inflamed and irritated." Peter Friedman, CBO of BRS, said that "I-Ease is an easily applied topical eye drop that replaces in the corneal surface what was normally present in the youthful, healthy eye." Dr. Maguire also added, "I-Ease uses BRS's patented core technology, known as S2RM TechnologyTM where stem cell released molecules from multiple stem cell types are used to formulate the drops." Maguire and Friedman further stated that molecules comprising the S2RM TechnologyTM replace the multitude of molecules that have been lost in the dry eye condition. Development at BRS' research laboratories for the last several years and recently completed clinical trials allowed for I-Ease to be released for sale in the US market in January 2011. BRS's I-Ease can be purchased online at: www.bioregenerativesciences.com. For more information, please email email@example.com, or call customer service at 877.892.9991.